Literature DB >> 18093940

Circulating tumor antigen-specific regulatory T cells in patients with metastatic melanoma.

Luis Vence1, A Karolina Palucka, Joseph W Fay, Tomoki Ito, Yong-Jun Liu, Jacques Banchereau, Hideki Ueno.   

Abstract

Although it is accepted that regulatory T cells (T regs) contribute to cancer progression, most studies in the field consider nonantigen-specific suppression. Here, we show the presence of tumor antigen-specific CD4(+) T regs in the blood of patients with metastatic melanoma. These CD4(+) T regs recognize a broad range of tumor antigens, including gp100 and TRP1 (melanoma tissue differentiation antigens), NY-ESO-1 (cancer/testis antigen) and survivin (inhibitor of apoptosis protein (IAP) family antigen). These tumor antigen-specific T regs proliferate in peripheral blood mononuclear cells (PBMC) cultures in response to specific 15-mer peptides, produce preferentially IL-10 and express high levels of FoxP3. They suppress autologous CD4(+)CD25(-) T cell responses in a cell contact-dependent manner and thus share properties of both naturally occurring regulatory T cells and type 1 regulatory T cells. Such tumor antigen-specific T regs were not detected in healthy individuals. These tumor antigen-specific T regs might thus represent another target for immunotherapy of metastatic melanoma.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18093940      PMCID: PMC2409236          DOI: 10.1073/pnas.0710557105

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  37 in total

Review 1.  IL-10-producing and naturally occurring CD4+ Tregs: limiting collateral damage.

Authors:  Anne O'Garra; Pedro L Vieira; Paulo Vieira; Anne E Goldfeld
Journal:  J Clin Invest       Date:  2004-11       Impact factor: 14.808

2.  Inducing and expanding regulatory T cell populations by foreign antigen.

Authors:  Karsten Kretschmer; Irina Apostolou; Daniel Hawiger; Khashayarsha Khazaie; Michel C Nussenzweig; Harald von Boehmer
Journal:  Nat Immunol       Date:  2005-10-23       Impact factor: 25.606

3.  Visualizing regulatory T cell control of autoimmune responses in nonobese diabetic mice.

Authors:  Qizhi Tang; Jason Y Adams; Aaron J Tooley; Mingying Bi; Brian T Fife; Pau Serra; Pere Santamaria; Richard M Locksley; Matthew F Krummel; Jeffrey A Bluestone
Journal:  Nat Immunol       Date:  2005-11-27       Impact factor: 25.606

4.  Oral tolerance in the absence of naturally occurring Tregs.

Authors:  Daniel Mucida; Nino Kutchukhidze; Agustin Erazo; Momtchilo Russo; Juan J Lafaille; Maria A Curotto de Lafaille
Journal:  J Clin Invest       Date:  2005-06-02       Impact factor: 14.808

5.  Recognition of a new ARTC1 peptide ligand uniquely expressed in tumor cells by antigen-specific CD4+ regulatory T cells.

Authors:  Helen Y Wang; Guangyong Peng; Zhong Guo; Ethan M Shevach; Rong-Fu Wang
Journal:  J Immunol       Date:  2005-03-01       Impact factor: 5.422

6.  CD4+CD25+ T cells inhibit both the induction and effector function of autoreactive T cells and represent a unique lineage of immunoregulatory cells.

Authors:  E Suri-Payer; A Z Amar; A M Thornton; E M Shevach
Journal:  J Immunol       Date:  1998-02-01       Impact factor: 5.422

Review 7.  Dendritic cells as therapeutic vaccines against cancer.

Authors:  Jacques Banchereau; A Karolina Palucka
Journal:  Nat Rev Immunol       Date:  2005-04       Impact factor: 53.106

8.  Single-cell analysis of normal and FOXP3-mutant human T cells: FOXP3 expression without regulatory T cell development.

Authors:  Marc A Gavin; Troy R Torgerson; Evan Houston; Paul DeRoos; William Y Ho; Asbjørg Stray-Pedersen; Elizabeth L Ocheltree; Philip D Greenberg; Hans D Ochs; Alexander Y Rudensky
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-14       Impact factor: 11.205

9.  Continuous control of autoimmune disease by antigen-dependent polyclonal CD4+CD25+ regulatory T cells in the regional lymph node.

Authors:  Eileen T Samy; Lucy A Parker; Colin P Sharp; Kenneth S K Tung
Journal:  J Exp Med       Date:  2005-09-19       Impact factor: 14.307

10.  CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production.

Authors:  A M Thornton; E M Shevach
Journal:  J Exp Med       Date:  1998-07-20       Impact factor: 14.307

View more
  77 in total

1.  Differential patterns of large tumor antigen-specific immune responsiveness in patients with BK polyomavirus-positive prostate cancer or benign prostatic hyperplasia.

Authors:  Giovanni Sais; Stephen Wyler; Tvrtko Hudolin; Irina Banzola; Chantal Mengus; Lukas Bubendorf; Peter J Wild; Hans H Hirsch; Tullio Sulser; Giulio C Spagnoli; Maurizio Provenzano
Journal:  J Virol       Date:  2012-05-30       Impact factor: 5.103

2.  Lentivirally engineered dendritic cells activate AFP-specific T cells which inhibit hepatocellular carcinoma growth in vitro and in vivo.

Authors:  Yang Liu; Lisa H Butterfield; Xiaohui Fu; Zhenshun Song; Xiaoping Zhang; Chongde Lu; Guanghui Ding; Mengchao Wu
Journal:  Int J Oncol       Date:  2011-04-13       Impact factor: 5.650

3.  Melanoma cells express ICOS ligand to promote the activation and expansion of T-regulatory cells.

Authors:  Natalia Martin-Orozco; Yufeng Li; Yijun Wang; Shijuan Liu; Patrick Hwu; Yong-Jun Liu; Chen Dong; Laszlo Radvanyi
Journal:  Cancer Res       Date:  2010-11-23       Impact factor: 12.701

Review 4.  Development of multi-epitope vaccines targeting wild-type sequence p53 peptides.

Authors:  Albert B DeLeo; Theresa L Whiteside
Journal:  Expert Rev Vaccines       Date:  2008-09       Impact factor: 5.217

Review 5.  Roles of regulatory T cells in cancer immunity.

Authors:  Yoshiko Takeuchi; Hiroyoshi Nishikawa
Journal:  Int Immunol       Date:  2016-05-09       Impact factor: 4.823

6.  Cancer-immune equilibrium: questions unanswered.

Authors:  Alka Bhatia; Yashwant Kumar
Journal:  Cancer Microenviron       Date:  2011-05-24

7.  Spontaneous high-titered IgG antibody responses against BCL-2 in patients with aggressive lymphomas.

Authors:  Carsten Zwick; Gerhard Held; Vera Hammermeister; Adnan Alahmad; Boris Kubuschok; Joerg Bittenbring; Manfred Ahlgrimm; Frank Neumann; Klaus-Dieter Preuss; Michael Pfreundschuh
Journal:  J Cancer Res Clin Oncol       Date:  2009-02-21       Impact factor: 4.553

8.  Elimination of IL-10-inducing T-helper epitopes from an IGFBP-2 vaccine ensures potent antitumor activity.

Authors:  Denise L Cecil; Gregory E Holt; Kyong Hwa Park; Ekram Gad; Lauren Rastetter; Jennifer Childs; Doreen Higgins; Mary L Disis
Journal:  Cancer Res       Date:  2014-04-28       Impact factor: 12.701

9.  Droplet encapsulation improves accuracy of immune cell cytokine capture assays.

Authors:  Yuan Yuan; Julie Brouchon; J Mauricio Calvo-Calle; Jing Xia; Li Sun; Xu Zhang; Kiera L Clayton; Fangfu Ye; David A Weitz; John A Heyman
Journal:  Lab Chip       Date:  2020-04-03       Impact factor: 6.799

10.  FOXP3 expression accurately defines the population of intratumoral regulatory T cells that selectively accumulate in metastatic melanoma lesions.

Authors:  Mojgan Ahmadzadeh; Aloisio Felipe-Silva; Bianca Heemskerk; Daniel J Powell; John R Wunderlich; Maria J Merino; Steven A Rosenberg
Journal:  Blood       Date:  2008-09-26       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.